uniQure (NASDAQ:QURE) Stock Price Down 15% After Analyst Downgrade

uniQure N.V. (NASDAQ:QURE) dropped 15% during trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $37.00 to $9.00. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure traded as low as $8.78 and last traded at $8.9260. Approximately 2,917,063 shares were traded during trading, an increase of 6% from the average daily volume of 2,757,464 shares. The stock had previously closed at $10.50.

Other equities research analysts have also issued reports about the stock. William Blair reissued a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Benchmark reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Mizuho reissued a “neutral” rating and issued a $12.00 price objective (down from $33.00) on shares of uniQure in a report on Tuesday. Wolfe Research initiated coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure currently has an average rating of “Hold” and an average target price of $34.33.

Insiders Place Their Bets

In other news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 6,217 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $148,337.62. Following the transaction, the chief financial officer directly owned 211,513 shares of the company’s stock, valued at approximately $5,046,700.18. This trade represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 50,598 shares of company stock valued at $1,248,588. Insiders own 4.79% of the company’s stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 earnings beat expectations — uniQure reported a smaller-than-expected loss and revenue slightly above consensus, which is a constructive near-term financial data point. Earnings Call Transcript
• Positive Sentiment: Some analysts still see upside — Chardan kept a buy rating while lowering its target to $16, signaling that at least one shop views the shares as a recovery/re‑risk opportunity. Chardan coverage
• Neutral Sentiment: Company will engage with FDA on next steps — uniQure said it’s evaluating Phase 3 development options and plans a follow-up Type B meeting with the FDA in Q2, which keeps the program alive but adds time and cost. Company Update
• Neutral Sentiment: Corporate governance change flagged — uniQure disclosed it will fall under the Dutch “large company” regime in 2026, a governance shift investors should monitor for board/ shareholder dynamics. Governance Risk
• Negative Sentiment: FDA rejected uniQure’s early‑approval pathway and requested a new randomized (sham‑controlled) Phase 3 study for AMT‑130 — that regulatory demand is the main cause of today’s share decline because it materially lengthens development timelines, increases costs, and raises trial risk. FDA story
• Negative Sentiment: Multiple analyst downgrades and big target cuts — firms including Cantor Fitzgerald, RBC, Mizuho and Wells Fargo cut targets and/or ratings this morning, signaling reduced near‑term conviction and pressuring sentiment. Analyst actions
• Negative Sentiment: Class‑action litigation piling up — several law firms have filed or solicited claims related to late‑2025 disclosures, adding legal overhang and potential monetary exposure. Class action notice

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QURE. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Aberdeen Group plc raised its stake in uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after buying an additional 738,897 shares in the last quarter. State Street Corp boosted its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of uniQure during the 2nd quarter worth about $29,217,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

The firm has a 50 day moving average of $23.17 and a two-hundred day moving average of $29.77. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The stock has a market cap of $559.36 million, a PE ratio of -2.06 and a beta of 0.73.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The company had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. Research analysts predict that uniQure N.V. will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.